Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Tislelizumab
Related studies linked through entity extraction aliases.
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE1
A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE2
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Mannatide Combined With CAPOX and Tislelizumab for Advanced Gastric Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
- Status
- RECRUITING
- Phase
- N/A